Thank you again for the quality writeup. Do we know if the FY25 guidance includes alternatives (oral and liraglutide), or is excluding all post-Q1 weight loss drugs completely?
It does. It includes everything they can & will comercialized legally through FY25. Orale, semaglutide & probably some expectation of their liraglutide.
FV to me means the price at which I buy or the average price I would not go above if I have to accumulate. It isn't really FV like you can read on other write ups. It's really a buying price including margin of safety.
PES & PS are forward ratios, based on forward revenues & income multiplied by forward shares counts. And why, it is because I said some time ago I was focusing on buying Hims between x2 & x3 F.P/S, which is around $25 based on actual guidance.
Thank you again for the quality writeup. Do we know if the FY25 guidance includes alternatives (oral and liraglutide), or is excluding all post-Q1 weight loss drugs completely?
It does. It includes everything they can & will comercialized legally through FY25. Orale, semaglutide & probably some expectation of their liraglutide.
Got it, thanks. Really not a bad growth rate!
As shared no, far from it. But the market doesn't believe it apparently...
how did you get $25 FV for Hims? also, how did you calculate PES and PS in two tables in your valuation thesis
FV to me means the price at which I buy or the average price I would not go above if I have to accumulate. It isn't really FV like you can read on other write ups. It's really a buying price including margin of safety.
As to how, the method is decribed here.
https://wealthyreadings.substack.com/p/investing-how-and-why
PES & PS are forward ratios, based on forward revenues & income multiplied by forward shares counts. And why, it is because I said some time ago I was focusing on buying Hims between x2 & x3 F.P/S, which is around $25 based on actual guidance.
Another great article
Thanks a lot 🙏